A Simple and Universal Nucleic Acid Assay Platform Based on Personal Glucose Meter Using SARS-CoV-2 N Gene as the Model

A simple, selective, and quantitative platform for point-of-care diagnostic of COVID-19 is urgently needed as a complement in areas where resources are currently relatively scarce. To meet the needs of early diagnosis and intervention, a proof-of-concept demonstration of a universal personal glucose...

Full description

Saved in:
Bibliographic Details
Published inBiosensors (Basel) Vol. 12; no. 4; p. 249
Main Authors Li, Tian, Pan, Rui, Wen, Yuhan, Xu, Jiaqi, Zhang, Liping, He, Suna, Liang, Gaofeng
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 15.04.2022
MDPI
Subjects
Acids
Antigens
Asymptomatic
Biomarkers
Coronaviruses
COVID-19
COVID-19 - diagnosis
Data analysis
Deoxyribonucleic acid
Diagnosis
Diagnostic tests
Disease transmission
DNA
Epidemics
Glucose
Humans
in vitro detection
N gene
Nucleic Acid Amplification Techniques
nucleic acid assay
Nucleic Acids
personal glucose meter
Point-of-Care Systems
Saliva
SARS-CoV-2
SARS-CoV-2 - genetics
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Sperm
Sucrose
Variance analysis
Viral diseases
China
SARS-CoV-2
in vitro detection
personal glucose meter
nucleic acid assay
Online AccessGet full text

Cover

More Information
Summary:A simple, selective, and quantitative platform for point-of-care diagnostic of COVID-19 is urgently needed as a complement in areas where resources are currently relatively scarce. To meet the needs of early diagnosis and intervention, a proof-of-concept demonstration of a universal personal glucose meter-based nucleic acid assay platform (PGM-NAAP) is presented, which converts to SARS-CoV-2 detection from glucose detection. By using magnetic bead separation together with the hand-held PGM for quantitative readout, PGM-NAAP achieves the 98 pM limit of detection for a sequence related to SARS-CoV-2. The ability to discriminate target nucleic acid from genomic DNA, the satisfactory spike recoveries of saliva and serum samples, as well as the good stability all together suggest the potential of the PGM-NAAP for the screening and diagnosis of suspected patients during the outbreaks of COVID-19 in resource-limited settings without sophisticated instruments. On the basis of these findings, PGM-NAAP can be expected to provide an accurate and convenient path for diagnosis of disease-associated nucleic acid.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2079-6374
2079-6374
DOI:10.3390/bios12040249